ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pancreatic Cancer
Colorectal Cancer
Non-Small-Cell Lung Carcinoma
Stomach Cancer
Prostatic Cancer
Esophageal Cancer
Neoplasm Metastasis

Adenocarcinoma trials near Chicago, IL, USA:

A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) (TroFuse-015)

(TPC) in participants with advanced/metastatic gastroesophageal adenocarcinoma. The primary hypothesis of this study is sacituzumab tirumote...

Active, not recruiting
Gastroesophageal Cancer
Drug: Supportive care measures
Biological: Sacituzumab tirumotecan

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Chicago, Illinois, United States and 168 other locations

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma...

Enrolling
Advanced Adenocarcinoma
Drug: BA3182

Phase 1

BioAtla

Chicago, Illinois, United States and 8 other locations

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

(CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma...

Enrolling
Gastroesophageal Junction Adenocarcinoma
Esophageal Cancer
Drug: Sonesitatug vedotin
Drug: Nivolumab

Phase 3

AstraZeneca
AstraZeneca

Chicago, Illinois, United States and 268 other locations

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma (MAPKeeper 301)

The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

Enrolling
Pancreatic Adenocarcinoma Metastatic
PDAC - Pancreatic Ductal Adenocarcinoma
Drug: mGnP
Drug: GnP

Phase 3

Immuneering Corporation

Chicago, Illinois, United States and 18 other locations

Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma (RiME)

The study population is advanced gastric, gastroesophageal, and esophageal adenocarcinoma participants who have failed upfront standard of c...

Active, not recruiting
Esophagus Cancer, Adenocarcinoma
Stomach Cancer, Adenocarcinoma
Drug: Rucaparib
Drug: Nivolumab

Phase 1, Phase 2

University of Kansas
University of Kansas

Chicago, Illinois, United States and 7 other locations

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

drug being developed for the treatment of pancreatic ductal adenocarcinoma (PDAC). This study will be divided into two phases, with the firs...

Enrolling
Metastatic Pancreatic Ductal Adenocarcinoma
PDAC
Drug: Irinotecan
Drug: Telisotuzumab adizutecan

Phase 2, Phase 3

AbbVie
AbbVie

Zion, Illinois, United States and 15 other locations

Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PRISM-1)

The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitab...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Gemcitabine
Drug: Nab-paclitaxel

Phase 3

Arcus Biosciences
Arcus Biosciences

Chicago, Illinois, United States and 118 other locations

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 302)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.

Active, not recruiting
PDAC - Pancreatic Ductal Adenocarcinoma
PDAC
Drug: 5-fluorouracil
Drug: leucovorin

Phase 3

Revolution Medicines
Revolution Medicines

Chicago, Illinois, United States and 59 other locations

Locations recently updated

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma...

Enrolling
Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Drug: Nivolumab
Drug: Pumitamig

Phase 2, Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Chicago, Illinois, United States and 160 other locations

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection comp...

Enrolling
Metastatic Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: 5-fluorouracil (5-FU)
Drug: Cisplatin

Phase 3

BeOne Medicines

Chicago, Illinois, United States and 93 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems